Navigation Links
Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
Date:12/7/2007

PRINCETON, N.J., Dec. 7 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today announced that it will receive an undisclosed milestone payment from its licensing partner, Centocor, Inc., for the submission of regulatory applications requesting approval of ustekinumab (CNTO 1275) in the United States and in Europe for the treatment of chronic moderate to severe plaque psoriasis by Centocor.

Ustekinumab is a human monoclonal antibody that binds to the cytokines IL-12 and IL-23 and was generated using Medarex's UltiMAb(R) technology. Medarex may receive future milestone payments and royalties should this product candidate progress to commercialization and achieve commercial sales.

"News of a first regulatory filing for approval for an antibody developed from Medarex technology is an important milestone for Medarex and marks a major achievement in translating the technology developed by our head of research, Dr. Nils Lonberg, into innovative and potentially significant treatments for many unmet medical needs," said Howard H. Pien, President and CEO of Medarex. "We believe that the ongoing development progress of ustekinumab and other antibody programs generated from Medarex's UltiMAb platform will continue to highlight the therapeutic importance and value creation opportunities of antibodies and our technology."

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 30 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase III clinical trials. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at http://www.medarex.com.

Medarex Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed herein may constitute forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; or similar statements are forward-looking statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risks associated with product development, unforeseen safety issues resulting from the administration of antibody products in humans, uncertainties concerning Centocor's activities under its agreement with Medarex, as well as risks detailed from time to time in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2006 and its quarterly reports on Form 10-Q. There can be no assurance that future milestone payments will be paid, whether the product development efforts will succeed, or whether other developed products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of Medarex's public disclosure filings are available from its investor relations department.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
2. Medarex to Present at the JPMorgan Small/Mid Cap Conference
3. PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM)
4. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
5. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
6. DaVita Receives Civil Complaint
7. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
8. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
9. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
10. Mayo Clinic Multidisciplinary Simulation Center Receives Distinction as an ACS-Accredited Education Institute
11. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... ... Premier Fitness Camp (PFC) and The Chopra Center for Wellbeing announced today the ... their world headquarters of Omni La Costa Resort & Spa in San Diego. , ... loss, personal development, a healthy lifestyle, or mental and physical healing. The week-long wellness ...
(Date:12/8/2016)... ... 2016 , ... STAT courier is pleased to announce that due to customer ... are expanding their presence in Dallas. One of the most exciting parts for STAT ... to the Dallas and Forth Worth market. STAT takes pride in treating their employees ...
(Date:12/8/2016)... AR (PRWEB) , ... December 08, 2016 , ... ... insurance and financial planning services from offices headquartered in Little Rock, has initiated ... Pantry. , According to the National Foundation to End Senior Hunger, Arkansas ranks ...
(Date:12/8/2016)... MS (PRWEB) , ... December 08, 2016 , ... The ... serve commercial and residential clients in and around the Hancock County area, is announcing ... the Hancock County Food Pantry. , The Hancock County Food Pantry has worked for ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... passage of the most comprehensive mental health systems reform legislation in more than ... the President, and the commitment of our elected officials to improving mental health ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... CITY , Dec. 8, 2016 ... US patents for improving the accuracy, reproducibility and ... images in long and small bone orthopaedic applications. ... approach to creating personalized orthopaedic restorations based on ... personalized orthopaedic restorations, the company harnesses the world,s ...
(Date:12/8/2016)... Dec. 8, 2016  A new study by a ... use of opioid therapy to treat chronic pain is ... of more harmful consequences, including death. Palliative ... Zankhana Mehta , M.D., authored the study which ... opioid therapy. The study was published in the December ...
(Date:12/8/2016)... 2016 Information products and services provider ... Scopus , the world,s largest abstract and citation database of ... for journals from over 5,000 publishers. The new set of metrics ... to and when to adjust a journal,s editorial strategy. ... , , ...
Breaking Medicine Technology: